このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MWX205

2026年6月8日 更新者:Shanghai Minwei Biotechnology Co., Ltd

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered MWX205 Injection in Adult Participants With Dyslipidemia

This study is being done to test a new injection called MWX205 in people with high cholesterol or fat levels in the blood (dyslipidemia).

Researchers will check if a single dose of MWX205 is safe and how the body reacts to it. They will also measure how quickly the drug enters the bloodstream and how long it stays in the body, and compare it with a placebo (inactive treatment).

The study will help decide the right dose and understand how this medicine could be used in future treatments.

The main questions this study aims to answer are:

  1. Is MWX205 safe after a single dose?
  2. How does the body process MWX205?
  3. Does MWX205 show any effect on the body related to cholesterol levels?

調査の概要

状態

まだ募集していません

詳細な説明

This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose study in which the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of MWX205 Injection will be assessed in adult participants with dyslipidemia.

Overall, 37 participants will be enrolled and assigned to 5 sequential cohorts (Cohorts 1 through 5).

Cohort 1 will enroll 5 participants and be randomized 3:2 to receive a single dose of MWX205 or placebo (3 participants receiving MWX205 and 2 receiving a placebo).

Cohorts 2 to 5 will be comprised of 8 participants per Cohort and randomized 3:1 to receive a single dose of MWX205 or placebo, respectively (6 participants receiving MWX205 Injection and 2 receiving a placebo).

Dosing in each cohort will be such that 2 participants (1 MWX205 Injection and 1 placebo) will be administered at least 24 hours before the remaining 3 participants (the first cohort) or 6 participants (cohorts 2-5). After dosing the first 2 participants on a separate day, a minimum of a 5-minute dosing interval for the remaining 3 participants (the first cohort), or 6 participants (cohorts 2-5) in the following cohort, is considered acceptable.

Continuation to dose the remaining 3 participants (Cohort 1) or 6 participants (Cohorts 2-5) will be at the investigator's discretion.

Each participant will participate in 1 cohort only, residing at the Clinical Research Unit (CRU) from Day -1 (the day before dosing) to Day 8.

研究の種類

介入

入学 (推定)

37

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  1. Adult participants with dyslipidemia will be enrolled in this study.
  2. The absence of clinically significant illness and surgery within 4 weeks prior to study drug administration.
  3. Participants must have fasting triglycerides greater than or equal to 150 mg/dL (1.7 mmol/L) and less than 500 mg/dL (5.7 mmol/L), and LDL-C greater than or equal to 70 mg/dL (1.8 mmol/L) at pre-screening and confirmation within 7 days before randomization.
  4. Have a body mass index within the range 18.5 to 40.0 kg/m2 (inclusive), with no plans to significantly alter diet or BMI over the course of study.
  5. Females of childbearing potential and males who are not surgically sterile (> 90 days since vasectomy with no viable sperm) will agree to use contraception from Screening until 6 months after the administration, OR females of non-reproductive potential

Exclusion Criteria:

  1. Positive pregnancy test or lactating female participant.
  2. Systolic BP lower than 90 or over 140 mmHg, diastolic BP lower than 40 or over 90 mmHg, HR less than 40 or over 100 bpm at screening.
  3. QTcF over 450 ms at screening.
  4. Consume more than 7 units for women or 14 units for men of alcohol per week within 8 weeks prior to screening (1 unit = 285 mL of beer 3.5%, 75 mL of wine 13.5%, or 25 mL of distilled alcohol 40%).
  5. Participants with established coronary artery disease, peripheral arterial disease, prior stroke, or other clinically significant atherosclerotic cardiovascular disease (such as stent placement or heart bypass, unstable angina or last known ejection fraction of <50%).
  6. History of intolerance to SC injection or relevant abdominal scarring (surgical, burns, etc.), or any skin conditions, including infections or open wounds, or dermatitis at the injection site that could interfere with the evaluation of injection reaction.
  7. Have taken any prescription medications that are specifically indicated for lowering serum TGs (e.g., fibric acid derivatives, niacin, and omega-3 fatty acids [>1 g/day]) or medications that interfere with absorption of dietary cholesterol or fats (e.g., bile acid sequestrants, orlistat) within 2 months prior to screening.
  8. Have received treatment with any liver-targeted siRNA therapy or ASO (Antisense Oligonucleotide) within12 months prior to screening.
  9. Use of ANGPTL3 or PCSK9-inhibiting monoclonal antibodies within 90 days prior to screening.
  10. Use of systemic glucocorticoid therapy for more than 14 consecutive days in the past year, or any glucocorticoid therapy (excluding topical, intra-ocular, intra-articular, intranasal, or inhaled preparations) within 1 month before screening.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:トリプル

武器と介入

参加者グループ / アーム
介入・治療
実験的:MWX205
Strength: 1ml: 200 mg Proposed dose levels for SAD study: 50, 200, 400, 800, and 1200 mg Administration: subcutaneous injection, recommended in the abdomen.
Each vial contains 200mg of MWX205 small nucleic acid, with water for injection as the solvent. The excipient, including sodium hydroxide and/or hydrochloric acid, may be added to adjust the pH to 6.5±0.2.
プラセボコンパレーター:Placebo
Administration: subcutaneous injection, recommended in the abdomen.
一致するプラセボ

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Incidence of TEAEs
時間枠:From Day 1 to Day 86
From Day 1 to Day 86
Incidence of SAEs
時間枠:From Day 1 to Day 86
From Day 1 to Day 86
Number of participants with abnormal vital signs
時間枠:From Day 1 to Day 86
Vital signs include tympanic body temperature, systolic and diastolic blood pressure, pulse rate, and respiratory rate
From Day 1 to Day 86
Number of participants with abnormal Physical examination findings
時間枠:From Day 1 to Day 337
Complete physical examinations include general appearance, mouth/dental (if required), neck (including thyroid & nodes), cardiovascular, respiratory, gastrointestinal, renal, neurological, musculoskeletal, skin, other
From Day 1 to Day 337
Number of participants with abnormal ECG readings
時間枠:From Day 1 to Day 337
12 Lead ECG: Triplicate readings to be taken within 2 to 5 minutes of each other. ECGs are to be taken after the participant has rested in the supine position for ≥ 5 minutes
From Day 1 to Day 337

二次結果の測定

結果測定
メジャーの説明
時間枠
Plasma PK parameters Cmax (Maximum observed plasma drug concentration directly determined from the plasma concentration-time profiles)
時間枠:Day 1, Day 2, Day 3
Non-compartmental analysis (NCA) will be used to calculate the PK parameters with Phoenix WinNonlin Software
Day 1, Day 2, Day 3
Plasma PK parameters- Tmax (Time to maximum observed plasma drug concentration)
時間枠:Day 1, Day 2, Day 3
Non-compartmental analysis (NCA) will be used to calculate the PK parameters with Phoenix WinNonlin Software
Day 1, Day 2, Day 3
Plasma PK parameters- AUC0-inf (Area under the plasma concentration-time curve from time 0 extrapolated to infinity.)
時間枠:Day 1, Day 2, Day 3
Non-compartmental analysis (NCA) will be used to calculate the PK parameters with Phoenix WinNonlin Software
Day 1, Day 2, Day 3
Plasma PK parameters- AUC0-last (Area under the plasma concentration-time curve, from time zero to the last time point with measurable analyte concentration)
時間枠:Day 1, Day 2, Day 3
Non-compartmental analysis (NCA) will be used to calculate the PK parameters with Phoenix WinNonlin Software
Day 1, Day 2, Day 3
Urine PK parameters- Fe (dose fraction of the drug in its original form excreted in urine after administration)
時間枠:Day 1, Day 2, Day 3
Non-compartmental analysis (NCA) will be used to calculate the PK parameters with Phoenix WinNonlin Software
Day 1, Day 2, Day 3
Urine PK parameters- Ae (cumulative excretion of the drug's original form in urine)
時間枠:Day 1, Day 2, Day 3
Non-compartmental analysis (NCA) will be used to calculate the PK parameters with Phoenix WinNonlin Software
Day 1, Day 2, Day 3

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Mohd Naguib bin Mohd Yunos, Dr.、Veritus Research

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年6月22日

一次修了 (推定)

2026年10月26日

研究の完了 (推定)

2027年11月8日

試験登録日

最初に提出

2026年6月4日

QC基準を満たした最初の提出物

2026年6月4日

最初の投稿 (実際)

2026年6月8日

学習記録の更新

投稿された最後の更新 (実際)

2026年6月10日

QC基準を満たした最後の更新が送信されました

2026年6月8日

最終確認日

2026年6月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • MWX205-101

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する